26 June 2018

JCO Simultaneous Publication at ASCO

cover

The phase III multinational, multicenter study of “Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations” shows dacomitinib to significantly improve overall survival. Results recommending the second-generation drug be considered as one of the standard treatment options were presented at the recent ASCO Annual Meeting in Chicago (J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994. [Epub ahead of print]).

Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Tony Mok, Chairman of Our Department of Clinical Oncology. Prof Mok’s research focuses on biomarker and molecular targeted therapy in lung cancer. He is the co-founder of the Lung Cancer Research Group, and has led multiple multinational studies leading to the establishment of the global standard on personalized medicine for lung cancer.

Read the full article: http://ascopubs.org/doi/abs/10.1200/JCO.2018.78.7994?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

More on our research: https://research.med.cuhk.edu.hk/

back